273 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28131714	119	Indolyl-naphthyl-maleimides as potent and selective inhibitors of protein kinase C-a/ß.	Novartis Institutes For Biomedical Research
28109791	44	Identification of a selective inhibitor of transforming growth factorß-activated kinase 1 by biosensor-based screening of focused libraries.	Chugai Pharmaceutical
1597853	2	A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1.	National Cancer Institute-Frederick
1992155	30	Design of potent protein kinase inhibitors using the bisubstrate approach.	Ura Cnrs 1309
2342075	11	Synthesis of quaternary amine ether lipids and evaluation of neoplastic cell growth inhibitory properties.	University of North Carolina
11454465	4	Synthesis of N-alkyl substituted indolocarbazoles as potent inhibitors of human cytomegalovirus replication.	Glaxosmithkline
27362616	41	G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitors: Current Trends and Future Perspectives.	Universit£
27288183	130	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.	Southeast University
27117263	51	Discovery and optimization of 1,7-disubstituted-2,2-dimethyl-2,3-dihydroquinazolin-4(1H)-ones as potent and selective PKC¿ inhibitors.	Takeda Pharmaceutical
26951753	336	Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors.	Novartis Institutes For Biomedical Research
26762835	342	Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).	Icahn School of Medicine At Mount Sinai
26071372	89	Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3.	Astellas Pharma
25808573	3	Neristatin 1 provides critical insight into bryostatin 1 structure-function relationships.	National Cancer Institute-Bethesda
25835317	63	Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.	Sichuan University
25633741	67	Discovery and profiling of a selective and efficacious Syk inhibitor.	Novartis Institutes For Biomedical Research
25766633	9	Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.	The University of Michigan Medical School
25437619	88	Design and synthesis of protein kinase C epsilon selective diacylglycerol lactones (DAG-lactones).	Seoul National University
25000588	72	Discovery of selective and orally bioavailable protein kinase C¿ (PKC¿) inhibitors from a fragment hit.	Abbvie Bioresearch Center
24913714	53	Discovery of a novel series of potent MK2 non-ATP competitive inhibitors using 1,2-substituted azoles as cis-amide isosteres.	Merck Research Laboratories
25589930	62	Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation.	Lexicon Pharmaceuticals
25462247	20	In vitro and in vivo characterization of a benzofuran derivative, a potential anticancer agent, as a novel Aurora B kinase inhibitor.	Fudan University
25313996	91	Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinase.	Merck Research Laboratories
25254961	32	Optimized protein kinase C¿ (PKC¿) inhibitors reveal only modest anti-inflammatory efficacy in a rodent model of arthritis.	Abbvie Bioresearch Center
24794745	20	Synthesis, biological, and biophysical studies of DAG-indololactones designed as selective activators of RasGRP.	National Institute of Industrial Technology
23434140	35	Substituted indolin-2-ones as p90 ribosomal S6 protein kinase 2 (RSK2) inhibitors: Molecular docking simulation and structure-activity relationship analysis.	East China University of Science and Technology
23301767	154	Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities.	University of Nottingham
23394126	170	Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).	Exelixis
23398373	88	Design and optimization of selective protein kinase C¿ (PKC¿) inhibitors for the treatment of autoimmune diseases.	Vertex Pharmaceuticals
23265875	78	Design and synthesis of tricyclic cores for kinase inhibition.	Abbott Bioresearch Center
22726925	216	Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.	Cellzome
23116168	42	Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.	Sichuan University
23039927	44	Multitargeted drug development: Discovery and profiling of dihydroxy substituted 1-aza-9-oxafluorenes as lead compounds targeting Alzheimer disease relevant kinases.	Martin-Luther-University Halle-Wittenberg
21797275	139	Structure-activity relationship and pharmacokinetic studies of sotrastaurin (AEB071), a promising novel medicine for prevention of graft rejection and treatment of psoriasis.	Novartis Institutes For Biomedical Research
22078216	146	2,6-Naphthyridines as potent and selective inhibitors of the novel protein kinase C isozymes.	Novartis Institutes For Biomedical Research
22625994	28	Structure-activity studies on the spiroketal moiety of a simplified analogue of debromoaplysiatoxin with antiproliferative activity.	Kyoto University
22533818	84	Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3a.	Technische Universit£T Darmstadt
22738630	76	Structure-based optimization of aminopyridines as PKC¿ inhibitors.	Vertex Pharmaceuticals
22537682	6	Inverse Virtual Screening allows the discovery of the biological activity of natural compounds.	Universit£
21435888	7	The synthesis and evaluation of indolylureas as PKCa inhibitors.	Procter & Gamble Pharmaceuticals
21141896	2	Discovery of (7R)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase.	P. Angeletti S.P.A. (Merck Research Laboratories)
21155605	39	Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.	Novartis Institutes For Biomedical Research
21128646	88	Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposure.	Merck Research Laboratories
20138512	82	Discovery of potent and bioavailable GSK-3beta inhibitors.	Roche Palo Alto
20153204	109	Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.	Nerviano Medical Sciences
20038108	19	Novel synthesis and structural characterization of a high-affinity paramagnetic kinase probe for the identification of non-ATP site binders by nuclear magnetic resonance.	Wyeth Research
19397322	58	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.	National Cancer Institute-Bethesda
9677190	49	Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.	University of California
14593182	34	Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.	Pfizer
9834166	8	Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity.	Virginia Polytechnic Institute and State University
18395443	37	Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.	Bristol-Myers Squibb
18359226	50	Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.	Bristol-Myers Squibb Research and Development
18077363	314	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.	University of Oxford
17983756	55	Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.	Osi Pharmaceuticals
17977729	40	Design and physicochemical properties of new fluorescent ligands of protein kinase C isozymes focused on CH/pi interaction.	Kyoto University
17339109	33	Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors.	Astellas Pharma
17284021	10	Conformationally constrained analogues of diacylglycerol (DAG). 27. Modulation of membrane translocation of protein kinase C (PKC) isozymes alpha and delta by diacylglycerol lactones (DAG-lactones) containing rigid-rod acyl groups.	National Cancer Institute-Frederick
16876403	85	Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure.	Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories
16460940	13	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis.	Hoffmann-La Roche
16220969	219	Designed multiple ligands. An emerging drug discovery paradigm.	Organon Laboratories
15999997	85	Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase.	Serono Pharmaceutical Research Institute
15380221	58	Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors.	Central Pharmaceutical Research Institute
14736244	8	Conformationally constrained analogues of diacylglycerol. 20. The search for an elusive binding site on protein kinase C through relocation of the carbonyl pharmacophore along the sn-1 side chain of 1,2-diacylglycerol lactones.	National Cancer Institute-Frederick
12672248	50	Kinase inhibitors: not just for kinases anymore.	Northwestern University
12954055	47	Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors.	Johnson and Johnson Pharmaceutical Research and Development
12801241	4	Conformationally constrained analogues of diacylglycerol. 19. Synthesis and protein kinase C binding affinity of diacylglycerol lactones bearing an N-hydroxylamide side chain.	National Cancer Institute-Frederick
12166950	208	Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.	Millennium Pharmaceuticals
8691452	1	Molecular modeling and site-directed mutagenesis studies of a phorbol ester-binding site in protein kinase C.	National Cancer Institute-Bethesda
8289196	7	New hexahydroxybiphenyl derivatives as inhibitors of protein kinase C.	University of North Carolina
10999477	40	Synthesis and PKC isozyme surrogate binding of indothiolactam-V, a new thioamide analogue of tumor promoting indolactam-V.	Kyoto University
10843211	38	Structure-activity relationship studies of flavopiridol analogues.	Mitotix
9990463	69	2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors.	Novartis Pharmaceuticals
	80	Synthesis and PKC inhibitory activities of balanol analogs with a cyclopentane substructure	TBA
16249345	25	Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.	Glaxosmithkline
15953730	13	RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: synthesis and biological evaluation.	Hoffmann-La Roche
22136433	67	7,8-dichloro-1-oxo-ß-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.	Ludwig-Maximilians University of Munich
22204902	9	Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.	Institute of The Sir Mortimer Jewish General Hospital
22014550	337	Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).	Ansaris
21999461	90	1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase.	RhôNe-Poulenc Rorer
21936542	143	Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.	Novartis Institute For Biomedical Research
21823617	58	9-substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors.	Chugai Pharmaceutical
21807510	31	Synthesis and biological evaluation of glycogen synthase kinase 3 (GSK-3) inhibitors: an fast and atom efficient access to 1-aryl-3-benzylureas.	Technische Universit£T Darmstadt
21880495	5	Chemical modifications of resveratrol for improved protein kinase C alpha activity.	University of Houston
21705217	60	Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38a MAP kinase inhibitors.	Bristol-Myers Squibb
21696964	12	Generation of 'Unnatural Natural Product' library and identification of a small molecule inhibitor of XIAP.	Keio University
20674350	63	Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.	Merck Research Laboratories
21548579	4	Hippolides A-H, acyclic manoalide derivatives from the marine sponge Hippospongia lachne.	Second Military Medical University
21596562	9	Design and synthesis of protein kinase Ca activators based on 'out of pocket' interactions.	Riken Advanced Science Institute
21561771	39	Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors.	Chugai Pharmaceutical
24900231	22	Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.	TBA
21035336	42	5-amino-pyrazoles as potent and selective p38a inhibitors.	Bristol-Myers Squibb Research and Development
20855207	26	Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.	Merck Research Laboratories
20817520	40	Role of the phenolic hydroxyl group in the biological activities of simplified analogue of aplysiatoxin with antiproliferative activity.	Kyoto University
19654408	2521	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).	Ambit Biosciences
10998351	24	Specificity and mechanism of action of some commonly used protein kinase inhibitors.	University of Dundee
20684591	87	Identification of orally available naphthyridine protein kinase D inhibitors.	Novartis Institutes For Biomedical Research
20382527	26	Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.	Bristol-Myers Squibb Research and Development
19894727	164	Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.	Wyeth Research
20223663	100	2-Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: optimization of human microsomal stability.	Wyeth Research
20188552	75	Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).	Wyeth Research
19884006	47	Hit to lead optimization of pyrazolo[1,5-a]pyrimidines as B-Raf kinase inhibitors.	Wyeth Research
19879134	94	Imidazo[1,2-a]pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4.	Cgi Pharmaceuticals
19864136	45	Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.	Wyeth Research
19854649	49	Discovery of highly potent and selective type I B-Raf kinase inhibitors.	Wyeth Research
20045644	32	Polar 3-alkylidene-5-pivaloyloxymethyl-5'-hydroxymethyl-gamma-lactones as protein kinase C ligands and antitumor agents.	Seoul National University
20093027	92	Discovery of 6-benzyloxyquinolines as c-Met selective kinase inhibitors.	Chugai Pharmaceutical
19945867	39	Ring-fused pyrazole derivatives as potent inhibitors of lymphocyte-specific kinase (Lck): Structure, synthesis, and SAR.	Taisho Pharmaceutical
19888761	52	Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer.	Hanmi Research Center
8882431	4	Antineoplastic agents. 340. Isolation and structural elucidation of bryostatins 16-18.	Arizona State University
	4	Benzo[c]quinoliziniums: A new family of inhibitors for protein kinase CK II	TBA
	42	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation	TBA
	230	Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives	TBA
	77	Synthesis and protein kinase C inhibitory activities of indane analogs of balanol	TBA
	70	Potent and selective PKC inhibitory 5-membered ring analogs of balanol with replacement of the carboxamide moiety	TBA
	90	Phenylamino-pyrimidine (PAP) — derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors	TBA
	8	Protein kinase C-α inhibitors; structure-activity relationships in bis-indole series	TBA
	40	Heteroatom effect in the PKC inhibitory activities of perhydroazepine analogs of balanol	TBA
	88	Novel PKC inhibitory analogs of balanol with replacement of the ester functionality	TBA
	40	Protein kinase C inhibitory activities of balanol analogs bearing carboxylic acid replacements	TBA
	2	Synthesis of the benzofuran analogue of ILV, a new protein kinase C (PKC) activator	TBA
	7	Conformationally constrained analogues of diacylglycerol (DAG). 4. Interaction of α-alkylidene-γ-lactones with protein kinase C (PK-C)	TBA
	4	Synthesis of ingenol analogs wth affinity for protein kinase C	TBA
	3	Conformationally constrained analogues of diacylglycerol. 5. 2,5-Dideoxy-3-O-tetradecanoyl-D-galactono-1,4-lactone: A superior homologue of 3-O-tetradecanoyl-2-deoxy-L-ribonolactone with PK-C binding affinity.	TBA
19438240	8	Design, synthesis, and biological activity of isophthalic acid derivatives targeted to the C1 domain of protein kinase C.	University of Helsinki
19379015	40	Conformationally constrained analogues of diacylglycerol (DAG). 31. Modulation of the biological properties of diacylgycerol lactones (DAG-lactones) containing rigid-rod acyl groups separated from the core lactone by spacer units of different lengths.	National Cancer Institute-Frederick
19364658	113	Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).	Wyeth Research
19285393	90	Discovery of 5-pyrrolopyridinyl-2-thiophenecarboxamides as potent AKT kinase inhibitors.	Glaxosmithkline
19109017	4	(-)-Cercosporamide derivatives as novel antihyperglycemic agents.	Daiichi Sankyo
19081248	12	Identification of small molecules that inhibit GSK-3beta through virtual screening.	Korea Research Institute of Chemical Technology
18707088	72	Conformationally constrained analogues of diacylglycerol. 30. An investigation of diacylglycerol-lactones containing heteroaryl groups reveals compounds with high selectivity for Ras guanyl nucleotide-releasing proteins.	National Cancer Institute-Frederick
18606543	68	2-Alkenylthieno[2,3-b]pyridine-5-carbonitriles: Potent and selective inhibitors of PKCtheta.	Wyeth Research
17848581	13	Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood.	Wyeth Research
17395590	2	Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.	University of Wisconsin
18072722	42	Synthesis, conformational analysis, and biological evaluation of 1-hexylindolactam-V10 as a selective activator for novel protein kinase C isozymes.	Kyoto University
17303421	56	Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors.	Roche Research Center
16789733	41	Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.	Bristol-Myers Squibb Pharmaceutical Research Institute
16765046	63	Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.	Chiron
16722637	39	Conformationally constrained analogues of diacylglycerol. 26. Exploring the chemical space surrounding the C1 domain of protein kinase C with DAG-lactones containing aryl groups at the sn-1 and sn-2 positions.	National Cancer Institute-Frederick
16682193	62	Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16640328	13	Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta.	Kyoto University
16570908	39	Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.	Pharmaceutical Research Institute
16539391	21	Branched diacylglycerol-lactones as potent protein kinase C ligands and alpha-secretase activators.	Research Institute of Pharmaceutical Sciences
16216497	67	Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection.	Abbott Bioresearch Center
16134942	19	Conformationally constrained analogues of diacylglycerol (DAG). 25. Exploration of the sn-1 and sn-2 carbonyl functionality reveals the essential role of the sn-1 carbonyl at the lipid interface in the binding of DAG-lactones to protein kinase C.	National Cancer Institute-Frederick
15943473	136	Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
15771419	134	Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.	Johnson & Johnson Pharmaceutical Research & Development
15711537	653	A small molecule-kinase interaction map for clinical kinase inhibitors.	Ambit Biosciences
15615512	21	Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.	Bristol-Myers Squibb Pharmaceutical Research Institute
15566298	34	The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase.	Bristol-Myers Squibb
15317463	16	Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activity.	Bristol-Myers Squibb Pharmaceutical Research Institute
15261294	17	Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine.	Michigan State University
15163204	18	Conformationally constrained analogues of diacylglycerol. 21. A solid-phase method of synthesis of diacylglycerol lactones as a prelude to a combinatorial approach for the synthesis of protein kinase C isozyme-specific ligands.	National Cancer Institute At Frederick
15149684	59	3-(7-Azaindolyl)-4-arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3.	Johnson & Johnson Pharmaceutical Research & Development
15125969	8	Design, synthesis, and structure-activity relationship of new isobenzofuranone ligands of protein kinase C.	Tohoku University
14552791	35	Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors.	Eli Lilly
12954072	46	New bivalent PKC ligands linked by a carbon spacer: enhancement in binding affinity.	Georgetown University Medical Center
12941331	96	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.	Johnson & Johnson Pharmaceutical Research & Development
12941324	66	Synthesis and binding selectivity of 7- and 15-decylbenzolactone-V8 for the C1 domains of protein kinase C isozymes.	Kyoto University
12824047	99	Novel IKK inhibitors: beta-carbolines.	Millennium Pharmaceuticals
12749884	126	Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.	Eli Lilly
12699375	10	Differential binding modes of diacylglycerol (DAG) and DAG lactones to protein kinase C (PK-C).	National Cancer Institute-Frederick
12672234	64	Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase.	Boehringer Ingelheim Pharmaceuticals
12540236	11	New amide-bearing benzolactam-based protein kinase C modulators induce enhanced secretion of the amyloid precursor protein metabolite sAPPalpha.	Georgetown University Medical Center
12270156	8	Synthesis and kinase inhibitory activity of 3'-(S)-epi-K-252a.	Cephalon
12039590	51	Pyrrolo[2,3-d]pyrimidines containing diverse N-7 substituents as potent inhibitors of Lck.	Abbott Bioresearch Center
11934592	24	Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor.	Merck Research Laboratories
11909733	30	Beta-carbolines as specific inhibitors of cyclin-dependent kinases.	Institute of Molecular and Cell Biology
11728178	15	Conformationally constrained analogues of diacylglycerol. 18. The incorporation of a hydroxamate moiety into diacylglycerol-lactones reduces lipophilicity and helps discriminate between sn-1 and sn-2 binding modes to protein kinase C (PK-C). Implications for isozyme specificity.	Seoul National University
11689073	4	Iridals are a novel class of ligands for phorbol ester receptors with modest selectivity for the RasGRP receptor subfamily.	University of Michigan Cancer Center
11597418	47	Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity.	Glaxosmithkline
11327599	25	Rational design, synthesis, and biological evaluation of rigid pyrrolidone analogues as potential inhibitors of prostate cancer cell growth.	Georgetotwn University
11266178	39	The amide hydrogen of (-)-indolactam-V and benzolactam-V8's plays a critical role in protein kinase C binding and tumor-promoting activities.	Kyoto University
11266177	26	The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.	Kyoto University
11206480	6	Synthesis of 7,8-disubstituted benzolactam-V8 and its binding to protein kinase C.	Institute of Organic Chemistry
31757666	314	Discovery and optimization of heteroaryl piperazines as potent and selective PI3K? inhibitors.	Merck
11012021	69	Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I.	Basf Bioresearch
10966739	28	Conformationally constrained analogues of diacylglycerol (DAG). 17. Contrast between sn-1 and sn-2 DAG lactones in binding to protein kinase C.	National Cancer Institute-Bethesda
30755337	95	Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952.	Japan Tobacco
10762046	7	Diacylglycerols with lipophilically equivalent branched acyl chains display high affinity for protein kinase C (PK-C). A direct measure of the effect of constraining the glycerol backbone in DAG lactones.	National Cancer Institute-Bethesda
10743939	63	Synthesis and biological activities of NB-506 analogues modified at the glucose group.	Banyu Tsukuba Research Institute
10715158	31	Conformationally constrained analogues of diacylglycerol (DAG). 16. How much structural complexity is necessary for recognition and high binding affinity to protein kinase C?	National Cancer Institute-Bethesda
30530196	32	Chemistry-oriented synthesis (ChOS) and target deconvolution on neuroprotective effect of a novel scaffold, oxaza spiroquinone.	Gachon University
10612598	29	4-Pyridin-5-yl-2-(3,4,5-trimethoxyphenylamino)pyrimidines: potent and selective inhibitors of ZAP 70.	Celltech Therapeutics
10612590	56	Synthesis and biological activities of NB-506 analogues: Effects of the positions of two hydroxyl groups at the indole rings.	Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories
31298542	108	Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design.	Chinese Academy of Sciences
10514283	8	Protein kinase C ligands based on tetrahydrofuran templates containing a new set of phorbol ester pharmacophores.	Seoul National University
31417666	55	Discovery of Selective, Orally Bioavailable Pyrazolopyridine Inhibitors of Protein Kinase C? (PKC?) That Ameliorate Symptoms of Experimental Autoimmune Encephalomyelitis.	Vertex Pharmaceuticals
10397502	36	Selective binding of bryostatin analogues to the cysteine rich domains of protein kinase C isozymes.	Stanford University
10360738	5	Synthesis and protein kinase C binding activity of benzolactam-V7.	Institute of Organic Chemistry
10340602	100	Synthesis and biological activities of topoisomerase I inhibitors, 6-N-amino analogues of NB-506.	Banyu Tsukuba Research Institute
10090785	63	Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones.	Novartis
10021922	10	Synthesis, computer modeling and biological evaluation of novel protein kinase C agonists based on a 7-membered lactam moiety.	University of Tokyo
31693351	473	Discovery of 4	TBA
31343875	34	Synthesis and Structure-Activity Relationship Correlations of Gnidimacrin Derivatives as Potent HIV-1 Inhibitors and HIV Latency Reversing Agents.	Toho University
9873742	5	Conformationally constrained analogues of diacylglycerol (DAG). 15. The indispensable role of the sn-1 and sn-2 carbonyls in the binding of DAG-lactones to protein kinase C (PK-C).	National Institutes of Health
30733087	53	A review on flavones targeting serine/threonine protein kinases for potential anticancer drugs.	China Pharmaceutical University
9873429	6	Conformationally constrained analogues of diacylglycerol (DAG). 14. Dissection of the roles of the sn-1 and sn-2 carbonyls in DAG mimetics by isopharmacophore replacement.	National Cancer Institute-Bethesda
9341921	7	Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.	Université
30384048	365	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.	University of Florida
9135029	29	Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCdelta and discovery of an ILV analogue of improved isozyme selectivity.	Georgetown University Medical Center
31526603	379	Structure-based rational design of staurosporine-based fluorescent probe with broad-ranging kinase affinity for kinase panel application.	Takeda Pharmaceutical
9003521	249	Synthesis and protein kinase C inhibitory activities of balanol analogs with replacement of the perhydroazepine moiety.	Eli Lilly
8960550	5	Conformationally constrained analogues of diacylglycerol. 13. Protein kinase C ligands based on templates derived from 2,3-dideoxy-L-erythro(threo)-hexono-1,4-lactone and 2-deoxyapiolactone.	National Cancer Institute-Bethesda
8893841	23	Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties.	Université
8709095	87	(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.	Eli Lilly
8691423	89	4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.	Ciba Pharmaceuticals
26505898	123	Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.	Novartis Institutes For Biomedical Research
8568825	13	Conformationally constrained analogues of diacylglycerol. 12. Ultrapotent protein kinase C ligands based on a chiral 4,4-disubstituted heptono-1,4-lactone template.	National Cancer Institute-Bethesda
8568819	6	Conformationally constrained analogues of diacylglycerol. 11. Ultrapotent protein kinase C ligands based on a chiral 5-disubstituted tetrahydro-2-furanone template.	National Cancer Institute-Bethesda
8568806	9	Conformationally constrained analogues of diacylglycerol. 10. Ultrapotent protein kinase C ligands based on a racemic 5-disubstituted tetrahydro-2-furanone template.	National Cancer Institute-Bethesda
8176711	18	Protein kinase C. Modeling of the binding site and prediction of binding constants.	National Cancer Institute-Bethesda
23803585	7	Effects of the methoxy group in the side chain of debromoaplysiatoxin on its tumor-promoting and anti-proliferative activities.	Kyoto University
7799398	5	The discovery of novel, structurally diverse protein kinase C agonists through computer 3D-database pharmacophore search. Molecular modeling studies.	National Cancer Institute-Bethesda
21388717	1	Glycoglycerolipid analogues inhibit PKC translocation to the plasma membrane and downstream signaling pathways in PMA-treated fibroblasts and human glioblastoma cells, U87MG.	University of Milan
7807122	4	New cytotoxic peroxylactones from the marine sponge, Plakinastrella onkodes.	Harbor Branch Oceanographic Institution
9834165	5	Isolation and structure elucidation of new PKCalpha inhibitors from Pinus flexilis.	Virginia Polytechnic and State University
17618015	13	Bioactive peroxides as potential therapeutic agents.	The Hebrew University of Jerusalem
11334563	5	Computational analysis of PKA-balanol interactions.	University of California At San Diego
10753478	11	Inhibition of protein kinase C(alpha) by dequalinium analogues: dependence on linker length and geometry.	The City University of New York
10052965	9	Syntheses and biological activities of rebeccamycin analogues. Introduction of a halogenoacetyl substituent.	Universit£
9572888	4	Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle.	Universit£
14505650	12	An aminopyridazine-based inhibitor of a pro-apoptotic protein kinase attenuates hypoxia-ischemia induced acute brain injury.	Northwestern University
27731641	5	Isolation of Phorbol Esters from Euphorbia grandicornis and Evaluation of Protein Kinase C- and Human Platelet-Activating Effects of Euphorbiaceae Diterpenes.	Kaohsiung Medical University
30274941	36	A novel 2,4-diaminopyrimidine derivative as selective inhibitor of protein kinase C theta prevents allograft rejection in a rat heart transplant model.	Astellas Pharma
29135244	5	Natural Products with Heteroatom-Rich Ring Systems.	University of Auckland
29558119	30	Bioactive Indolocarbazoles from the Marine-Derived Streptomyces sp. DT-A61.	Zhejiang University
30026041	139	Synthesis and anticancer activity of novel bisindolylhydroxymaleimide derivatives with potent GSK-3 kinase inhibition.	University College Cork
29945794	193	ROCK inhibitors 2. Improving potency, selectivity and solubility through the application of rationally designed solubilizing groups.	Vertex Pharmaceuticals
29545102	159	Discovery of a highly potent orally bioavailable imidazo-[1, 2-a]pyrazine Aurora inhibitor.	Merck
29870245	39	Discovery of Novel Small-Molecule Inhibitors of NF-?B Signaling with Antiinflammatory and Anticancer Properties.	University of Colorado
29688013	81	Fragment-Based Drug Discovery of Potent Protein Kinase C Iota Inhibitors.	Agency For Science, Technology and Research (A*Star)
29107425	90	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.	Korea Institute of Science & Technology (Kist)
29860841	140	?-Arylidene Diacylglycerol-Lactones (DAG-Lactones) as Selective Ras Guanine-Releasing Protein 3 (RasGRP3) Ligands.	Seoul National University
29853332	50	Benzofuro[3,2-d]pyrimidines inspired from cercosporamide CaPkc1 inhibitor: Synthesis and evaluation of fluconazole susceptibility restoration.	Universit£
28259529	31	Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.	The Ohio State University
28699740	294	Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure.	Takeda Pharmaceutical
28991459	71	Methyl 3-(3-(4-(2,4,4-Trimethylpentan-2-yl)phenoxy)-propanamido)benzoate as a Novel and Dual Malate Dehydrogenase (MDH) 1/2 Inhibitor Targeting Cancer Metabolism.	Dongguk University
28478927	46	Discovery of novel substituted benzo-anellated 4-benzylamino pyrrolopyrimidines as dual EGFR and VEGFR2 inhibitors.	Martin-Luther-University Halle-Wittenberg
28392275	24	Exploring the influence of indololactone structure on selectivity for binding to the C1 domains of PKC?, PKC?, and RasGRP.	National Institute of Industrial Technology
27943581	8	Reverse Biosynthesis: Generating Combinatorial Pools of Drug Leads from Enzyme-Mediated Fragmentation of Natural Products.	The University of Sydney
27128528	42	Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects.	Harvard Medical School
26469307	7	Phosphorylation of Capsaicinoid Derivatives Provides Highly Potent and Selective Inhibitors of the Transcription Factor STAT5b.	University of Leipzig
11121615	32	Synthesis and in vitro opioid activity profiles of DALDA analogues.	Clinical Research Institute of Montreal
18804034	9	Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries.	Duke University Medical Center
17585751	48	Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties.	Amgen
16236500	26	Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors.	Johnson & Johnson Pharmaceutical
16279769	28	Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of 1-thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1H)- pyrazole derivatives.	Sapienza University of Rome
15689148	19	Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors.	Shanghai Institute of Materia Medica
15664516	21	Specificity and affinity of natural product cyclopentapeptide inhibitors against A. fumigatus, human, and bacterial chitinases.	University of Dundee
15026054	55	Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum.	Cnrs
	127	DISCOVERY AND STRUCTURE-ACTIVITY STUDIES OF A NOVEL SERIES OF PYRIDO[2,3-d]PYRIMIDINE TYROSINE KINASE INHIBITORS	Parke-Davis Pharmaceutical Research